Lineage Cell Therapeutics, Inc. Debt and Equity Securities, Unrealized Gain (Loss)
Lineage Cell Therapeutics, Inc. (LCTX) reported Debt and Equity Securities, Unrealized Gain (Loss) of -$150.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss · last filed 2023-08-10
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for the quarter ending 2023-06-30 was -$150.00K.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $40.00K.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for the quarter ending 2022-12-31 was -$517.00K.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for the quarter ending 2022-09-30 was -$233.00K.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for fiscal 2022 was -$2.19M.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for fiscal 2021 was -$2.30M.
- Lineage Cell Therapeutics, Inc. debt and equity securities, unrealized gain (loss) for fiscal 2020 was -$3.78M.
| Period end | Debt and Equity Securities, Unrealized Gain (Loss) 3 month | Debt and Equity Securities, Unrealized Gain (Loss) 6 month | Debt and Equity Securities, Unrealized Gain (Loss) 9 month | Debt and Equity Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$150.00K 10-Q · filed 2023-08-10 | -$110.00K 10-Q · filed 2023-08-10 | -$627.00K derived: sum of 3 quarters · filed 2023-08-10 | -$860.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $40.00K 10-Q · filed 2023-05-11 | -$477.00K derived: sum of 2 quarters · filed 2023-05-11 | -$710.00K derived: sum of 3 quarters · filed 2023-05-11 | -$1.42M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-12-31 | -$517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$750.00K derived: sum of 2 quarters · filed 2023-03-09 | -$1.46M derived: sum of 3 quarters · filed 2023-08-10 | -$2.19M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$233.00K 10-Q · filed 2022-11-10 | -$942.00K derived: sum of 2 quarters · filed 2023-08-10 | -$1.68M 10-Q · filed 2022-11-10 | -$3.35M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-06-30 | -$709.00K 10-Q · filed 2023-08-10 | -$1.44M 10-Q · filed 2023-08-10 | -$3.12M derived: sum of 3 quarters · filed 2023-08-10 | -$5.57M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$735.00K 10-Q · filed 2023-05-11 | -$2.41M derived: sum of 2 quarters · filed 2023-05-11 | -$4.86M derived: sum of 3 quarters · filed 2023-05-11 | -$4.27M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$4.13M derived: sum of 2 quarters · filed 2023-03-09 | -$3.54M derived: sum of 3 quarters · filed 2023-03-09 | -$2.30M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$2.45M 10-Q · filed 2022-11-10 | -$1.86M derived: sum of 2 quarters · filed 2022-11-10 | -$621.00K 10-Q · filed 2022-11-10 | $3.08M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $590.00K 10-Q · filed 2022-08-11 | $1.83M 10-Q · filed 2022-08-11 | $5.53M derived: sum of 3 quarters · filed 2022-08-11 | $3.53M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.24M 10-Q · filed 2022-05-12 | $4.94M derived: sum of 2 quarters · filed 2022-05-12 | $2.94M derived: sum of 3 quarters · filed 2022-05-12 | -$1.21M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.70M derived: sum of 2 quarters · filed 2022-03-10 | -$2.44M derived: sum of 3 quarters · filed 2022-03-10 | -$3.78M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$2.00M 10-Q · filed 2021-11-10 | -$6.15M derived: sum of 2 quarters · filed 2021-11-10 | -$7.49M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$4.15M 10-Q · filed 2021-08-12 | -$5.48M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |